These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37047086)

  • 41. Measurement of pre-treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients.
    Peng F; Chen F; Wen H; Bai J; Tian Y
    Int J Rheum Dis; 2022 Aug; 25(8):844-850. PubMed ID: 35694730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neutrophil/platelet to lymphocyte ratio in monitoring of response to TNF-α inhibitors in psoriatic patients.
    Najar Nobari N; Shahidi Dadras M; Nasiri S; Abdollahimajd F; Gheisari M
    Dermatol Ther; 2020 Jul; 33(4):e13457. PubMed ID: 32319132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The potency of common proinflammatory cytokines measurement for revealing the risk and severity of anxiety and depression in psoriasis patients.
    Tong N; Zhang Y; Yang A; Dai X; Hao S
    J Clin Lab Anal; 2022 Sep; 36(9):e24643. PubMed ID: 35944185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.
    Loft N; Egeberg A; Isufi D; Rasmussen MK; Bryld LE; Dam TN; Ajgeiy KK; Bertelsen T; Skov L
    Acta Derm Venereol; 2023 Nov; 103():adv12616. PubMed ID: 37987625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
    Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
    Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pro-inflammatory versus anti-inflammatory cytokines in psoriatic patients (case-control study).
    Elbana AM; Elgamal E; Hashim O; Emran TM; Alkhrsawy AA
    J Cosmet Dermatol; 2022 Nov; 21(11):6302-6307. PubMed ID: 35869799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis.
    Wang X; Kaiser H; Kvist-Hansen A; McCauley BD; Skov L; Hansen PR; Becker C
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of Malassezia in the activation of Interleukin (IL)-23/IL-17 axis in Psoriasis.
    Fang H; Hou Y; Zhuang H; Wang C
    New Microbiol; 2022 Apr; 45(2):130-137. PubMed ID: 35699562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interleukin-1β measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis.
    Kayakabe K; Kuroiwa T; Sakurai N; Ikeuchi H; Kadiombo AT; Sakairi T; Kaneko Y; Maeshima A; Hiromura K; Nojima Y
    Rheumatology (Oxford); 2012 Sep; 51(9):1639-43. PubMed ID: 22596214
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
    Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
    Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
    Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveals Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists.
    Hoffmann JHO; Knoop C; Enk A; Hadaschik EN
    Acta Derm Venereol; 2021 Sep; 101(10):adv00568. PubMed ID: 34590148
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum cytokine measurements and biological therapy of psoriasis - Prospects for personalized treatment?
    Solberg SM; Sandvik LF; Eidsheim M; Jonsson R; Bryceson YT; Appel S
    Scand J Immunol; 2018 Dec; 88(6):e12725. PubMed ID: 30307657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis.
    Loft N; Bregnhøj A; Fage S; Nielsen CH; Enevold C; Zachariae C; Iversen L; Skov L
    Dermatol Ther; 2021 Nov; 34(6):e15106. PubMed ID: 34418225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.
    Yamauchi PS; Bagel J
    J Drugs Dermatol; 2015 Mar; 14(3):244-53. PubMed ID: 25738846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.
    Piaserico S; Cazzaniga S; Chimenti S; Giannetti A; Maccarone M; Picardo M; Peserico A; Naldi L;
    J Am Acad Dermatol; 2014 Feb; 70(2):257-62.e3. PubMed ID: 24355410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
    van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
    Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.
    Zaba LC; Suárez-Fariñas M; Fuentes-Duculan J; Nograles KE; Guttman-Yassky E; Cardinale I; Lowes MA; Krueger JG
    J Allergy Clin Immunol; 2009 Nov; 124(5):1022-10.e1-395. PubMed ID: 19895991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.